Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Ambrisentan in Pulmonary Arterial Hypertension
NCT00554619Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2008
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by GSK. Primary endpoints: Number of Participants With Any Adverse Event up to 140.57 weeks and Number of Participants With Adverse Events Categorized by Severity up to 140.57 weeks. Started Feb 2008; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00554619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00554619.